Vakaramoko Diaby to Sirolimus
This is a "connection" page, showing publications Vakaramoko Diaby has written about Sirolimus.
Connection Strength
0.719
-
Diaby V, Adunlin G, Montero AJ. Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88. J Med Econ. 2014 Apr; 17(4):248-9.
Score: 0.475
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
Score: 0.122
-
Diaby V, Adunlin G, Zeichner SB, Avancha K, Lopes G, Gluck S, Montero AJ. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Sep; 147(2):433-41.
Score: 0.122